IPTACOPAN, LNP023
CLNP023C12001B
Phase 3 small_molecule active
Quick answer
IPTACOPAN, LNP023 for Paroxysmal Nocturnal Hemoglobinuria (PNH) is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active